Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with Bevacizumab.

Abstract

BACKGROUND/AIM:

Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment. Thereafter, she developed cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary hypertension, left ventricular diastolic dysfunction and pericardial effusion, and was discontinued from the regimen with bevacizumab.

CONCLUSION:

Although clinically-effective, the severe cardiotoxicity of bevacizumab developed after over 20 courses of treatment prompted us to look for optimal chemotherapy prescription in order to achieve a better clinical outcome.

• Authors: Jian Chen, Fengcai Du, Baohong Hu, Cheng Chi, Hongjin Chu, Lixin Jiang, Peng Li, Zhaohua Gong
• Journal: Anticancer research (Anticancer Res) Vol. 37 Issue 8 Pg. 4557-4561 (08 2017) ISSN: 1791-7530 [Electronic] Greece
• PMID: 28739752 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• Biomarkers
• Bevacizumab

Topics

• Angiogenesis Inhibitors (adverse effects)
• Antineoplastic Agents (adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab (adverse effects)
• Biomarkers
• Biopsy
• Cardiotoxicity
• Colonoscopy
• Colorectal Neoplasms (complications, diagnosis, drug therapy)
• Female
• Heart Diseases (diagnosis, etiology)
• Humans
• Middle Aged
• Tomography, X-Ray Computed